Rapid Therapeutic Science Laboratories, Inc.: key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2022): $0
Net Income/Loss (FY2022): -$1.8M
Total Assets (FY2022): $2.3M
Total Equity (FY2022): -$3.1M
Cash Flows from Operating Activities (FY2022): -$1.2M

Source: Rapid Therapeutic Science Laboratories, Inc. 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.

Rapid Therapeutic Science Laboratories, Inc.: key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2022): $0
Net Income/Loss (FY2022): -$1.8M
Total Assets (FY2022): $2.3M
Total Equity (FY2022): -$3.1M
Cash Flows from Operating Activities (FY2022): -$1.2M

Source: Rapid Therapeutic Science Laboratories, Inc. 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.